Reference
·Supporting source
Thailand pharmaceutical cold-chain share of distribution
~22-26%
Cold-chain (2-8 degrees Celsius) and ultra-cold (sub-zero) pharmaceutical distribution accounted for an estimated 22-26% of total pharma distribution value in Thailand in 2024 per PReMA and DKSH disclosures, materially up from roughly 14-16% in 2018. The growth reflects biologics, oncology, vaccines, and insulin penetration in the market. DKSH, Zuellig, and DCH Auriga operate the dominant temperature-controlled distribution networks, with validated GDP-compliant warehouses in Bangkok metropolitan and Chiang Mai, plus secondary regional hubs in Khon Kaen and Hat Yai. Investment in last-mile cold-chain to upcountry hospitals remains a margin and capability differentiator.
Figure in context
Cold-chain (2-8 degrees Celsius) and ultra-cold (sub-zero) pharmaceutical distribution accounted for an estimated 22-26% of total pharma distribution value in Thailand in 2024 per PReMA and DKSH disclosures, materially up from roughly 14-16% in 2018. The growth reflects biologics, oncology, vaccines, and insulin penetration in the market. DKSH, Zuellig, and DCH Auriga operate the dominant temperature-controlled distribution networks, with validated GDP-compliant warehouses in Bangkok metropolitan and Chiang Mai, plus secondary regional hubs in Khon Kaen and Hat Yai. Investment in last-mile cold-chain to upcountry hospitals remains a margin and capability differentiator.
Cold-chain (2-8 degrees Celsius) and ultra-cold (sub-zero) pharmaceutical distribution accounted for an estimated 22-26% of total pharma distribution value in Thailand in 2024 per PReMA and DKSH disclosures, materially up from roughly 14-16% in 2018. The growth reflects biologics, oncology, vaccines, and insulin penetration in the market. DKSH, Zuellig, and DCH Auriga operate the dominant temperature-controlled distribution networks, with validated GDP-compliant warehouses in Bangkok metropolitan and Chiang Mai, plus secondary regional hubs in Khon Kaen and Hat Yai. Investment in last-mile cold-chain to upcountry hospitals remains a margin and capability differentiator.
Time scope
2024 (sector composition)
Source basis
Supporting source
Interpretation notes
What this tells you
Cold-chain (2-8 degrees Celsius) and ultra-cold (sub-zero) pharmaceutical distribution accounted for an estimated 22-26% of total pharma distribution value in Thailand in 2024 per PReMA and DKSH disclosures, materially up from roughly 14-16% in 2018. The growth reflects biologics, oncology, vaccines, and insulin penetration in the market. DKSH, Zuellig, and DCH Auriga operate the dominant temperature-controlled distribution networks, with validated GDP-compliant warehouses in Bangkok metropolitan and Chiang Mai, plus secondary regional hubs in Khon Kaen and Hat Yai. Investment in last-mile cold-chain to upcountry hospitals remains a margin and capability differentiator.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical distribution and wholesale revenue (2020-2024)
Pharmaceutical Research and Manufacturers Association, Ministry of Public Health Drug Information Center, Thai FDA
Thailand pharmaceutical distributor market share (2024)
DKSH Group investor disclosures, Zuellig Pharma corporate filings, PReMA member surveys
Thailand pharmacy chain store count (2020-2024)
Boots Thailand corporate disclosures, Watsons CK Hutchison investor materials, Pharmacy Council of Thailand registry
DKSH Thailand healthcare segment revenue (2020-2024)
DKSH Group annual reports, DKSH Q4 trading updates, SIX Swiss Exchange disclosures
Thai FDA new drug registration approvals (2020-2024)
Thai Food and Drug Administration annual report, Ministry of Public Health, PReMA regulatory tracking
Government Pharmaceutical Organisation (GPO) state procurement
Government Pharmaceutical Organisation annual report, Ministry of Public Health, National Health Security Office
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.